Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Meropenem

FDA-approved product (injectable, injection), marketed as Meropenem, Meropenem And Sodium Chloride In Duplex Container, Merrem Iv.

Registered studies
50+
Lab records
263
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Meropenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial meningitis
  • Bacteriemia
  • Infection
  • Infectious meningitis
  • Meningitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH02

Repurposing investigation

Meropenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli99.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 16 of 17 lab records
  • E. coli: measured active in 38 of 38 lab records
  • K. pneumoniae: measured active in 172 of 208 lab records
Open Meropenem in ChEMBL Registered studies below
Show the latest 150 of 263 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Meropenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trials to Reduce the Risk of Antimicrobial Resistance

    NCT01570192 · start 2010-09

    Registered record
    Registry ID
    NCT01570192
    Conditions
    Bacterial Pneumonia
    Interventions
    IV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h; Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.; tobramycin nebulization
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-09
    Completion
    2015-04
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionIV meropenem; I.V. Meropenem; Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h +3 more
    PhasePhase 2
    Registry statusTerminated

  • Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)

    NCT00771316 · start 2008-12

    Registered record
    Registry ID
    NCT00771316
    Conditions
    Urinary Tract Infections
    Interventions
    MK0826 (ertapenem); Comparator: meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-12
    Completion
    2009-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionMK0826 (ertapenem); Comparator: meropenem
    PhasePhase 3
    Registry statusTerminated

  • Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients

    NCT00410527 · start 2006-08-11

    Registered record
    Registry ID
    NCT00410527
    Conditions
    Bacterial Infections
    Interventions
    Merrem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-08-11
    Completion
    2007-05-22
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionMerrem
    PhasePhase 4
    Registry statusCompleted

  • Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

    NCT00153634 · start 2004-03

    Registered record
    Registry ID
    NCT00153634
    Conditions
    Cystic Fibrosis; Chronic Bronchitis
    Interventions
    IV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin; IV meropenem; IV piperacillin-tazobactam; IV ticarcillin-clavulanate; IV tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-11
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Chronic Bronchitis
    InterventionIV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

    NCT00462878 · start 2002-11

    Registered record
    Registry ID
    NCT00462878
    Conditions
    Allogenic Blood Stem Cell Transplantation; Febrile Neutropenia
    Interventions
    Meropenem; Vancomycin; Teicoplanin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-11
    Completion
    2009-04
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogenic Blood Stem Cell Transplantation; Febrile Neutropenia
    InterventionMeropenem; Vancomycin; Teicoplanin
    PhaseNot recorded
    Registry statusCompleted